Murine models of ovarian cancer for preclinical testing of targeted therapeutics: has their time arrived?

Cell Cycle. 2012 Feb 1;11(3):430-1. doi: 10.4161/cc.11.3.19275. Epub 2012 Feb 1.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • BRCA1 Protein / metabolism
  • BRCA2 Protein / metabolism
  • Bevacizumab
  • Disease Models, Animal
  • Drug Evaluation, Preclinical*
  • Female
  • Humans
  • Mice
  • Mutation
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Tumor Microenvironment / drug effects
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • BRCA1 Protein
  • BRCA2 Protein
  • Tumor Suppressor Protein p53
  • Bevacizumab